Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 5/20 | 0.53 |
| ▸ | LIPE | Q05469 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365689 | 0.86 | MRGPRX4 (0.66) | LMNAL3MBTL1MAPK1GAAMAPT | |
| SCHEMBL10436236 | 0.82 | MAPK1 (0.63) | LMNAL3MBTL1MAPK1GAAMAPT | |
| SCHEMBL2365700 | 0.81 | L3MBTL1 (0.64) | LMNAL3MBTL1MAPK1GAAMAPT | |
| SCHEMBL3640462 | 0.81 | KDM4E (0.64) | LMNAL3MBTL1MAPK1GAAMAPT | |
| SCHEMBL19032083 | 0.81 | L3MBTL1 (0.57) | LMNAL3MBTL1MAPK1GAAMAPT | |
| SCHEMBL22469765 | 0.81 | MRGPRX4 (0.77) | LMNAMRGPRX4 | |
| SCHEMBL30334648 | 0.81 | MAPK1 (0.55) | LMNAL3MBTL1MAPK1GAAMAPT | |
| SCHEMBL5552615 | 0.80 | MAPT (0.62) | L3MBTL1MAPK1GAAMAPTTDP1 | |
| SCHEMBL6531818 | 0.80 | MAPK1 (0.75) | LMNAL3MBTL1MAPK1GAAMAPT | |
| SCHEMBL10515255 | 0.80 | RAB9A (0.65) | LMNAL3MBTL1MAPTTDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2362730-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010059618-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-0348002-B1 | Herbicidal acrylonitrile derivatives | SHELL INT RESEARCH (NL) | 1995-04-12 | — | — | EP | disclosed |
| US-4988385-A | Plant growth regulators, antigrowth agents for plants | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1991-01-29 | — | — | US | disclosed |
| EP-0348002-A2 | Herbicidal acrylonitrile derivatives | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HSD11B1, HSD17B11, HSD3B1 | LMNA 2393/4885L3MBTL1 4221/4885MAPK1 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.